Blog Category

Press Releases

Top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101)

, , ,

/

7 September 2022

Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4 th Annual Longevity Therapeutics Summit

,

/

4 July 2022

Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million

,

/

30 June 2022

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15 th SCWD International Congress

,

/

27 June 2022

Results of the Combined General Meeting on June 21, 2022

,

/

22 June 2022

Biophytis presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease

,

/

16 June 2022

Convening of Another Combined General Meeting at a Later Date

, , ,

/

3 June 2022

Biophytis announces its participation at the BIO International Convention in San Diego from the 13 th to the 16 th of June

,

/

12 May 2022

Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022

, , ,

/

19 April 2022

Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022

,

/

7 April 2022

Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program

,

/

3 February 2022

Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for €3 million

,

/

22 December 2021